HKSE:02591 (China)
Â
Ordinary Shares - Class H
HK$
7.6
+0.38 (+5.26%)
Aug 7
Business Description
Guangzhou Innogen Pharmaceutical Group Co Ltd
ISIN : CNE1000071Q7
Share Class Description:
HKSE:02591: Ordinary Shares - Class HTotal Employee Number:
193Compare
Compare
Traded in other countries / regions
02591.Hong Kong Index Membership
Hong Kong Stock Connect IPO Date
2025-08-15Description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.25 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.51 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y Total Revenue Growth Rate Estimate | 154.01 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.79 | |||||
9-Day RSI | 50.53 | |||||
14-Day RSI | 46.43 | |||||
3-1 Month Momentum % | -35.18 | |||||
6-1 Month Momentum % | -69.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.93 | |||||
Quick Ratio | 2.7 | |||||
Cash Ratio | 2.39 | |||||
Days Inventory | 1527.32 | |||||
Days Sales Outstanding | 19.61 | |||||
Days Payable | 3787.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.01 | |||||
Operating Margin % | -260.83 | |||||
Net Margin % | -259.77 | |||||
EBITDA Margin % | -250.87 | |||||
FCF Margin % | -241.83 | |||||
OCF Margin % | -225.05 | |||||
ROE % | -40.83 | |||||
ROA % | -29.98 | |||||
ROIC % | -184.2 | |||||
ROC (Joel Greenblatt) % | -1250.92 | |||||
ROCE % | -40.18 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 23.95 | |||||
PB Ratio | 2.98 | |||||
Price-to-Tangible-Book | 3.04 | |||||
EV-to-EBIT | -5.87 | |||||
EV-to-EBITDA | -6.05 | |||||
EV-to-Revenue | 15.17 | |||||
EV-to-FCF | -6.27 | |||||
| Price-to-Net-Current-Asset-Value | 3.28 | |||||
| Price-to-Net-Cash | 4.58 | |||||
Earnings Yield (Greenblatt) % | -17.04 | |||||
FCF Yield % | -10.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guangzhou Innogen Pharmaceutical Group Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 144.623 | ||
| EPS (TTM) (HK$) | -0.822 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 46.43 | ||
| 14-Day ATR (HK$) | 0.722869 | ||
| 20-Day SMA (HK$) | 7.7495 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (HK$) | 6.73 - 74 | ||
| Shares Outstanding (Mil) | 456.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guangzhou Innogen Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guangzhou Innogen Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guangzhou Innogen Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Guangzhou Innogen Pharmaceutical Group Co Ltd(HKSE:02591)'s stock price today?
The current price of HKSE:02591 is HK$7.60. The 52 week high of HKSE:02591 is HK$74.00 and 52 week low is HK$6.73.
When is next earnings date of Guangzhou Innogen Pharmaceutical Group Co Ltd(HKSE:02591)?
The next earnings date of Guangzhou Innogen Pharmaceutical Group Co Ltd(HKSE:02591) is .
Does Guangzhou Innogen Pharmaceutical Group Co Ltd(HKSE:02591) pay dividends? If so, how much?
Guangzhou Innogen Pharmaceutical Group Co Ltd(HKSE:02591) does not pay dividend.
Press Release
Articles on Guangzhou Innogen Pharmaceutical Group Co Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers